Rezultati pretraživanja
  1. prije 10 sati

    Okay I think I am bullish on too many biotech names: , , , , , , , , , , , , , , , , , , , Extreme long-shots small pos: Researching:

    Prikaži ovu nit
  2. prije 13 sati

    (1of3) I'm buying betw. $2.65-$3. Rezafungin is a solid product in Phase 3, reading out later 2020. In Sep CDTX signed a $568mm (potential) deal for EX-U.S. & Japan rights (see pic). Recent cap. raise through rights offering & above deal is done. Technicals good, see chart

    Prikaži ovu nit
  3. 5. velj
    Odgovor korisniku/ci

    dropping below $3.00/share from $4.40 is a red-line🚷for me. Expected more institutional support, esp trading as high as $4.00 from CANTOR analyst Ms Chen’s comments referencing Wuhan-nCoV/CLOUDBREAK. More appropriate to speak of REZAFUNGIN value. Doesn’t smell right.

  4. 4. velj
    Odgovor korisniku/ci

    I wonder why? Rezafungin seems to be a decent drug in need? Kind of sends the wrong message to investors.

  5. 4. velj
    Odgovor korisniku/ci

    Yes, market-manipulation at it’s best. Still, I think REZAFUNGIN drug is important and valuable and ‘back-stabbers’ I mean ‘back-stoppers’ BVF and Stonepine Capital know it. Kind of sucks individual investors have to be subjugated to this trading pattern. Schizophrenic!

  6. 4. velj

    trading not v shareholder friendly trading pattern last week. Asking for Rights Offer from existing shareholders and then trading down for a week. Anyone able analyze the trades last five (5) days after CANTOR’S comments on CLOUDBREAK and Wuhan nCoV outbreak?

    Prikaži ovu nit
  7. 4. velj

    Meanwell tops on the perennial under-performer list back under 3, near 7, near 12.

  8. 4. velj

    That rights offering at $2.51/share is looking a lot less attractive as we approach the expiration date.

  9. 4. velj
    Odgovor korisnicima i sljedećem broju korisnika:

    What about Cidara Therapeutics’ REZAFUNGIN, currently in Phase-3 (ReSTORE)trial for candidemia. Not sure if trial includes ‘a pregnant patient.’

  10. 2. velj
  11. 1. velj

    Looking worse than ever. -7.90 % change recently

  12. 31. sij
    Odgovor korisniku/ci

    NICE, shows conviction.

  13. 31. sij
  14. 31. sij

    : New Insider Filing on Chief Financial Officer JAMES E. LEVINE:

  15. 31. sij
  16. 30. sij

    SELL ALERT: I have just sold . The stock price dropped below 88% of the original (averaged) purchase price.

  17. 30. sij

    a bit volatility -5.20 % change recently

  18. 29. sij
  19. 29. sij
  20. 29. sij

    Cidara Therapeutics Shares Down 5.6%

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.